来那度胺作为晚期肝细胞癌二线治疗的疗效生物标志物探索
本单臂研究纳入55例索拉非尼进展后Child-Pugh A级晚期肝细胞癌患者,接受来那度胺25 mg/日口服(每4周第1-21天)。6个月无进展生存率为9.1%,早期甲胎蛋白应答与更高疾病控制率和更长无进展生存相关,血管应答与结局无关,高基线B细胞百分比与疾病控制和更长生存相关。
要点
- 来那度胺25 mg/日(每4周第1-21天)二线治疗晚期肝细胞癌,6个月无进展生存率9.1%。
- 早期甲胎蛋白应答(4周内下降>20%)与更高疾病控制率(76% vs 22%,P=.001)和更长无进展生存(P=.020)相关。
- 治疗前高B细胞百分比与疾病控制(70% vs 36%,P=.010)、更长无进展生存(P<.001)和总生存(P=.042)相关。
核心结论
- 来那度胺作为晚期肝细胞癌二线治疗表现出中等活性,其免疫调节作用应进一步探索。
研究设计与样本
- 单臂研究,纳入55例确诊晚期肝细胞癌、索拉非尼治疗进展且Child-Pugh A级肝功能患者。
- 患者接受来那度胺25 mg/日口服,每4周第1-21天给药,主要终点为6个月无进展生存率。
- 早期甲胎蛋白应答定义为治疗前4周内甲胎蛋白较基线下降>20%。
- 血管应答采用动态对比增强磁共振成像评估,定义为治疗2周后Ktrans下降>40%。
- 同时分析外周血淋巴细胞亚群百分比。
主要发现
- 客观缓解率为13%,疾病控制率为53%,6个月无进展生存率为9.1%。
- 中位无进展生存期为1.8个月,中位总生存期为8.9个月。
- 早期甲胎蛋白应答者疾病控制率76% vs 无应答者22%(P=.001),无进展生存更长(P=.020)。
- 血管应答与任何治疗结局均无关联。
- 治疗前高B细胞百分比者疾病控制率70% vs 低B细胞百分比者36%(P=.010),无进展生存更长(P<.001),总生存更长(P=.042)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lenalidomide has immunomodulatory and anti-angiogenic effects and showed moderate anti-tumour efficacy in patients with. advanced hepatocellular carcinoma (HCC) AIM: To explore potential biomarkers of lenalidomide efficacy as second-line therapy for HCC. METHODS: Eligible patients were diagnosed with advanced HCC, documented progression on sorafenib, and Child-Pugh class A liver function. Patients received 25 mg/day lenalidomide orally on days 1-21 every 4 weeks. The primary endpoint was 6 month progression-free survival rate. Early α-fetoprotein response was defined as a > 20% decline of α-fetoprotein levels from baseline within the first 4 weeks of treatment. Vascular response, evaluated using dynamic contrast-enhanced magnetic resonance imaging, was defined as a > 40% decline in Ktrans after 2 weeks of treatment. The percentage of peripheral blood lymphocyte subsets were also analysed. RESULTS: Fifty-five patients were enrolled. The response rate was 13%, and the disease-control rate was 53%. The 6 month progression-free survival rate was 9.1%. The median progression-free and overall survival was 1.8 months and 8.9 months respectively. Early α-fetoprotein response was significantly associated with higher disease-control rate (76% vs 22%, P = .001) and longer progression-free survival (P = .020). Vascular response was not associated with any treatment outcomes. Patients with a high pre-treatment B cell percentage were more likely to have disease control (70% vs 36%, P = .010) and exhibited longer progression-free survival (P < .001) and overall survival (P = .042). CONCLUSIONS: Lenalidomide exhibited moderate activity as second-line therapy for advanced HCC. Its immunomodulatory effects should be further explored (www.clinicaltrials.gov NCT01545804).
引用
- Shao YY, Chen BB, Ou DL, et al. Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy. Aliment Pharmacol Ther. 2017. PMID: 28815645. doi:10.1111/apt.14270
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。